Recipharm has partnered with biotechnology company Aptahem, for the formulation of Apta-1 drug candidate.
The aptamer-based drug candidate is intended to treat life-threatening condition sepsis, a potentially fatal condition which involves a general inflammatory response, known as systemic inflammatory response syndrome (SIRS), caused by an infection. Recipharm will develop an injectable formulation for the upcoming Phase 1 study.
“We are pleased to be able to contribute to the development of Aptahem’s leading drug candidate which has the potential to meet the major medical needs that exist for sepsis patients,” says Anders Högdin, Ph.D., Senior Sales Director at Recipharm. “Recipharm has extensive experience in developing drugs for clinical trials, as well as in commercial manufacturing and we believe that our team’s expertise will be a very valuable asset during this new collaboration.”
Follows the positive results of Apta-1’s exploratory sepsis study
The partnership follows the positive results of Apta-1’s exploratory sepsis study with non-human primates (NHP) which provided a greater understanding of the anticoagulant, anti-inflammatory and immunomodulatory effects of the candidate and continued to support its multifunctional potential within its therapeutic area.
